SG11201907496RA - Cyclic di-nucleotides compounds for the treatment of cancer - Google Patents
Cyclic di-nucleotides compounds for the treatment of cancerInfo
- Publication number
- SG11201907496RA SG11201907496RA SG11201907496RA SG11201907496RA SG11201907496RA SG 11201907496R A SG11201907496R A SG 11201907496RA SG 11201907496R A SG11201907496R A SG 11201907496RA SG 11201907496R A SG11201907496R A SG 11201907496RA SG 11201907496R A SG11201907496R A SG 11201907496RA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- international
- andover
- august
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 125000004122 cyclic group Chemical group 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 241001333452 Bridelia insulana Species 0.000 abstract 1
- 241000721662 Juniperus Species 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6587—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having two phosphorus atoms as ring hetero atoms in the same ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIPO I PCT Hu omit VIII °nolo OH lit mil loollowo oimIE (10) International Publication Number WO 2018/152450 Al (51) International Patent Classification: A61P 31/04 (2006.01) CO7F 9/6574 (2006.01) A61K 31/7084 (2006.01) C07H 19/213 (2006.01) CO7F 9/6527 (2006.01) A61P 37/04 (2006.01) (21) International Application Number: PCT/US2018/018556 (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 17 February 2018 (17.02.2018) English English Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 62/460,562 17 February 2017 (17.02.2017) US 62/479,169 30 March 2017 (30.03.2017) US 62/551,645 29 August 2017 (29.08.2017) US 62/551,647 29 August 2017 (29.08.2017) US 62/551,668 29 August 2017 (29.08.2017) US (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 6-10, Koishikawa 4-Chome Bunkyo-ku, Tokyo, 112-8088 (JP). (72) Inventors: KIM, Dae-Shik; 79 Dascomb Road, Andover, Massachusetts 01810 (US). FANG, Frank; 16 Greybirch Road, Andover, Massachusetts 01810 (US). ENDO, At- sushi; 311 Lowell Street, Andover, Massachusetts 01810 (US). CHOI, Hyeong-Wook; 39 Juniper Road, Andover, Massachusetts 01810 (US). HAO, Ming-Hong; 138 Quin- cy Shore Drive, #173, Quincy, Massachusetts 02171 (US). BAO, Xingfeng; 993 Main Street, Concord, Massachusetts 01742 (US). HUANG, Kuan-Chun; 7 Manning Street, Lexington, Massachusetts 02421 (US). (74) Agent: WALTERS, Todd R. et al.; BUCHANAN INGERSOLL & ROONEY PC, P. 0. Box 1404, Alexan- dria, Virginia 22313-1404 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 00 1-1 (54) Title: CYCLIC DI-NUCLEOTIDES COMPOUNDS FOR THE TREATMENT OF CANCER C (57) : Provided herein are compounds useful for the treatment of cancer. O
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460562P | 2017-02-17 | 2017-02-17 | |
| US201762479169P | 2017-03-30 | 2017-03-30 | |
| US201762551668P | 2017-08-29 | 2017-08-29 | |
| US201762551647P | 2017-08-29 | 2017-08-29 | |
| US201762551645P | 2017-08-29 | 2017-08-29 | |
| PCT/US2018/018556 WO2018152450A1 (en) | 2017-02-17 | 2018-02-17 | Cyclic di-nucleotides compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907496RA true SG11201907496RA (en) | 2019-09-27 |
Family
ID=61521844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907496RA SG11201907496RA (en) | 2017-02-17 | 2018-02-17 | Cyclic di-nucleotides compounds for the treatment of cancer |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20200055883A1 (en) |
| EP (3) | EP4008403A1 (en) |
| JP (2) | JP6672532B2 (en) |
| KR (1) | KR102645790B1 (en) |
| CN (3) | CN110536719A (en) |
| AU (1) | AU2018221170B2 (en) |
| CA (1) | CA3053932A1 (en) |
| CL (1) | CL2019002304A1 (en) |
| CO (1) | CO2019008783A2 (en) |
| CY (1) | CY1126855T1 (en) |
| DK (1) | DK3582853T3 (en) |
| ES (1) | ES2906299T3 (en) |
| HR (1) | HRP20220110T1 (en) |
| HU (1) | HUE057665T2 (en) |
| IL (1) | IL268721B (en) |
| JO (1) | JOP20190194B1 (en) |
| LT (1) | LT3582853T (en) |
| MA (1) | MA47501A (en) |
| MD (1) | MD3582853T2 (en) |
| MX (1) | MX394380B (en) |
| PE (1) | PE20191686A1 (en) |
| PH (1) | PH12019501914B1 (en) |
| PL (1) | PL3582853T3 (en) |
| PT (1) | PT3582853T (en) |
| RS (1) | RS62842B1 (en) |
| SG (1) | SG11201907496RA (en) |
| SI (1) | SI3582853T1 (en) |
| SM (1) | SMT202200054T1 (en) |
| TW (1) | TWI766948B (en) |
| UA (1) | UA125310C2 (en) |
| WO (2) | WO2018152453A1 (en) |
| ZA (1) | ZA201906111B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170192A1 (en) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | Cyclic dinucleotide |
| UA126863C2 (en) | 2017-01-20 | 2023-02-15 | Аркус Байосайєнсіз, Інк. | AZOLOPYRIMIDINES FOR THE TREATMENT OF CANCER DISEASES |
| HUE069643T2 (en) | 2017-03-27 | 2025-03-28 | Hydro Quebec | Salts for use in electrolyte mixtures or as electrode additives |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugates and methods of use thereof for selective delivery of immune-modulatory agents |
| PE20210156A1 (en) | 2017-11-10 | 2021-01-26 | Takeda Pharmaceuticals Co | STING MODULATING COMPOUNDS AND METHODS OF PREPARATION AND USE |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019161054A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| TWI833744B (en) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-cyclic dinucleotides |
| TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
| CA3101623A1 (en) * | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods for the treatment of bladder cancer |
| AU2019322722A1 (en) * | 2018-08-16 | 2020-10-15 | Eisai R&D Management Co., Ltd. | Salts of compounds and crystals thereof |
| MX2021002764A (en) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Compositions for the treatment of disease with immune stimulatory conjugates. |
| WO2020135715A1 (en) * | 2018-12-29 | 2020-07-02 | 上海济煜医药科技有限公司 | Compound for tumor immunity and application thereof |
| AU2020267486A1 (en) | 2019-05-09 | 2021-11-11 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as STING modulators |
| TWI826690B (en) * | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | Substituted eneoxindoles and uses thereof |
| EP3993809B1 (en) * | 2019-07-01 | 2024-10-09 | Eisai R&D Management Co., Ltd. | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP2022177332A (en) * | 2019-10-24 | 2022-12-01 | 日東電工株式会社 | Method for producing oligonucleotide |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| KR20220167275A (en) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | cancer treatment methods |
| WO2021252904A1 (en) | 2020-06-11 | 2021-12-16 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| TW202216211A (en) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | Anti-asgr1 antibody conjugates and uses thereof |
| CN111909223A (en) * | 2020-07-17 | 2020-11-10 | 清华大学 | Cyclic dinucleotide covalent modification and preparation method and application thereof |
| EP4228681A1 (en) | 2020-10-14 | 2023-08-23 | Boehringer Ingelheim International GmbH | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
| US20220168330A1 (en) | 2020-11-09 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| CN115974974A (en) * | 2022-09-16 | 2023-04-18 | 上海大学 | Polypeptide compound with anti-inflammatory activity and preparation method and application thereof |
| WO2024182569A2 (en) | 2023-02-28 | 2024-09-06 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| EP1740192B1 (en) | 2004-03-15 | 2012-06-13 | David K. R. Karaolis | Cyclic dinucleotide for stimulating the immune of inflammatory response |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
| CN102199183B (en) | 2010-03-26 | 2013-12-18 | 北京大学 | C-di-GMP, analogues thereof and preparation method thereof |
| KR20150022996A (en) * | 2012-06-08 | 2015-03-04 | 아두로 바이오테크 | Compositions and methods for cancer immunotherapy |
| KR20150095668A (en) * | 2012-12-13 | 2015-08-21 | 아두로 바이오테크, 인코포레이티드 | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| ES2982836T3 (en) * | 2013-04-29 | 2024-10-17 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| EP2992000B1 (en) | 2013-05-03 | 2020-07-08 | The Regents of The University of California | Cyclic di-nucleotide induction of type i interferon |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| SMT201900635T1 (en) | 2013-05-18 | 2020-01-14 | Univ California | Compositions and methods for activating |
| EP3071209A4 (en) | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| EP3071229A4 (en) | 2013-11-22 | 2017-05-10 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| ES2692226T3 (en) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Cyclic dinucleotides as STING modulators |
| JP6762030B2 (en) | 2014-11-20 | 2020-09-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | New Th1-inducible adjuvants and their uses by combining different nucleic acid adjuvants |
| WO2016096174A1 (en) | 2014-12-16 | 2016-06-23 | Invivogen | Fluorinated cyclic dinucleotides for cytokine induction |
| WO2016096577A1 (en) * | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| WO2016100261A2 (en) | 2014-12-17 | 2016-06-23 | Lipogen Llc | Method of treating cancer with cgamp or cgasmp |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| PE20171448A1 (en) * | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING DEPENDENT ON THE INTERFERON GENE STIMULATOR |
| WO2017011622A1 (en) | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions that induce rig-i-and other pattern recongnition receptors |
| CA3030582A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| CN108137641B (en) | 2015-08-13 | 2022-04-01 | 默沙东公司 | Cyclic dinucleotide compounds as sting agonists |
| US9809597B2 (en) | 2015-08-20 | 2017-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
| KR20180040706A (en) | 2015-09-01 | 2018-04-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Immune cells having increased immunity or resistance to immunosuppressive cytokines and uses thereof |
| US10906930B2 (en) | 2015-10-28 | 2021-02-02 | Chinook Therapeutics, Inc. | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling |
| RU2020113165A (en) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | CYCLIC PURINE DINUCLEOTIDES AS STING MODULATORS |
| JP6801956B2 (en) | 2015-12-04 | 2020-12-16 | 株式会社エクセディ | Motorcycle clutch device |
| WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| WO2017123669A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| CN114751950B (en) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | Cyclic dinucleotide compounds and methods of use |
| MX2018012266A (en) | 2016-04-07 | 2019-05-30 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators. |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| JOP20170188A1 (en) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | Cyclic dinucleotides as sting agonists |
| EP3574018A4 (en) | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
| UY37695A (en) | 2017-04-28 | 2018-11-30 | Novartis Ag | BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME |
-
2018
- 2018-02-16 US US16/486,954 patent/US20200055883A1/en not_active Abandoned
- 2018-02-17 PT PT187080320T patent/PT3582853T/en unknown
- 2018-02-17 CN CN201880025317.7A patent/CN110536719A/en active Pending
- 2018-02-17 KR KR1020197027073A patent/KR102645790B1/en active Active
- 2018-02-17 CA CA3053932A patent/CA3053932A1/en active Pending
- 2018-02-17 JO JOP/2019/0194A patent/JOP20190194B1/en active
- 2018-02-17 RS RS20220079A patent/RS62842B1/en unknown
- 2018-02-17 DK DK18708032.0T patent/DK3582853T3/en active
- 2018-02-17 SM SM20220054T patent/SMT202200054T1/en unknown
- 2018-02-17 PE PE2019001715A patent/PE20191686A1/en unknown
- 2018-02-17 MD MDE20200009T patent/MD3582853T2/en unknown
- 2018-02-17 HU HUE18708032A patent/HUE057665T2/en unknown
- 2018-02-17 PL PL18708032T patent/PL3582853T3/en unknown
- 2018-02-17 EP EP21208462.8A patent/EP4008403A1/en not_active Withdrawn
- 2018-02-17 US US15/898,533 patent/US10246480B2/en active Active
- 2018-02-17 HR HRP20220110TT patent/HRP20220110T1/en unknown
- 2018-02-17 EP EP18709835.5A patent/EP3582854A1/en not_active Withdrawn
- 2018-02-17 PH PH1/2019/501914A patent/PH12019501914B1/en unknown
- 2018-02-17 WO PCT/US2018/018561 patent/WO2018152453A1/en unknown
- 2018-02-17 JP JP2019544817A patent/JP6672532B2/en active Active
- 2018-02-17 CN CN202410024195.7A patent/CN117866030A/en active Pending
- 2018-02-17 CN CN201880021349.XA patent/CN110461416B/en active Active
- 2018-02-17 JP JP2019544725A patent/JP2020510638A/en active Pending
- 2018-02-17 MA MA047501A patent/MA47501A/en unknown
- 2018-02-17 EP EP18708032.0A patent/EP3582853B1/en active Active
- 2018-02-17 MX MX2019009796A patent/MX394380B/en unknown
- 2018-02-17 UA UAA201909860A patent/UA125310C2/en unknown
- 2018-02-17 LT LTEPPCT/US2018/018556T patent/LT3582853T/en unknown
- 2018-02-17 SG SG11201907496RA patent/SG11201907496RA/en unknown
- 2018-02-17 AU AU2018221170A patent/AU2018221170B2/en active Active
- 2018-02-17 ES ES18708032T patent/ES2906299T3/en active Active
- 2018-02-17 WO PCT/US2018/018556 patent/WO2018152450A1/en active IP Right Grant
- 2018-02-17 SI SI201830553T patent/SI3582853T1/en unknown
- 2018-02-21 TW TW107105846A patent/TWI766948B/en active
-
2019
- 2019-02-15 US US16/277,522 patent/US10618930B2/en active Active
- 2019-08-13 CO CONC2019/0008783A patent/CO2019008783A2/en unknown
- 2019-08-14 CL CL2019002304A patent/CL2019002304A1/en unknown
- 2019-08-15 IL IL268721A patent/IL268721B/en unknown
- 2019-09-16 ZA ZA2019/06111A patent/ZA201906111B/en unknown
-
2020
- 2020-02-04 US US16/781,352 patent/US11339188B2/en active Active
-
2022
- 2022-01-26 CY CY20221100065T patent/CY1126855T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907496RA (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201906395PA (en) | Blockchain based data processing method and device | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201908171TA (en) | Compounds and compositions for treating hematological disorders | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201903427UA (en) | Deodorizing agent comprising zinc neodecanoate | |
| SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds | |
| SG11201903833VA (en) | Tray system for transfer, counting, storage and disposal of surgical instruments | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201804095YA (en) | Rim brake system and a tire | |
| SG11201901472TA (en) | Combination therapies for the treatment of hepatocellular carcinoma |